Table 4 Differences in clinical features between defined groups of untreated PDR patients.

Variable	Contrast	Protein	Median protein levels (pg/ml)			P value
Variable	Contrast	Protein	Group 1	Group 2	Group 3	P value
Primary indication for vitrectomy	VH versus VMT/TRD
		IGFBP1	2815	681		0.009
		PDGF-BB	0.361	0.000		0.007
Neovascularisation activity	0 + 1 versus 2
		VEGF-ELISA	465	3010		< 0.001
		VEGFA	5250	29,006		< 0.001
		PlGF-ELISA	43.51	219.71		< 0.001
		PlGF	190	855		< 0.001
		MCP-1	3770	4403		0.003
Degree of haemorrhage	0 + 1 versus 2 + 3
		CTGF-ELISA	255,755	521,370		0.003
		IGFBP3-ELISA	6293	8121		0.005
		HGF	490	754		0.001
		MCP-1	3494	4276		0.002
		MMP-9	28.86	51.81		0.005
		PDGF-BB	0.000	0.514		< 0.001
	0 + 1 versus 2 + 3
		MMP-9	23.63	64.99		< 0.001
Diabetes type	Type 1 versus 2
		MCP-1	3494	4182		0.003
		PlGF	189	531		0.004
		VEGFA	4540	20,936		0.004
		GDF-15	5213	6944		0.002
New vessel location	0 + 1 versus 2 versus 3 + 4
New vessel location		ANGPT1	3.50	9.03	13.50	0.001

The null hypothesis that all medians are equal was analysed using the Kruskal–Wallis test. P values represent the significance of differences between group medians. Significant differences (P < 0.01) are given. Variables are defined in Table 1.
VH Vitreal haemorrhage, VMT Vitreo-macular traction, TRD Traction retinal detachment.

Quick links

Search